Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward

Approved vaccines prevent 2 to 3 million deaths per year. There is a lack of equitable access to vaccines in the low- and middle-income developing nations. Challenges in the life cycle of vaccine production include process development, lead time, intellectual property, and local vaccine production. A robust and stable manufacturing process and constant raw material supplies over decades is critical. In a continuously evolving vaccine landscape, the need of the hour for developing nations is to manufacture their own vaccines besides having supply security, control over production scheduling and sustainability, control of costs, socio-economic development, and rapid response to local epidemics. There is a need for capacity building of workforce development, technology transfer, and financial support. Technology transfer has improved vaccine access and reduced prices of vaccines. Capacity building for the manufacturing of vaccines in developing countries has always been an area of paramount importance and more so in a pandemic situation.

Automated summary

Approved vaccines prevent 2 to 3 million deaths per year, but there is a lack of equitable access to vaccines in low- and middle-income developing nations. Challenges in vaccine production include process development, intellectual property, and local production. Developing nations need to manufacture their own vaccines to ensure supply security, control costs, promote socio-economic development, and respond to local epidemics.